Works by Ray, Kausik K.
Results: 121
Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials.
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 3, p. 493, doi. 10.1007/s10557-022-07413-0
- By:
- Publication type:
- Article
Statin Therapy Dose and Risk of New-Onset Diabetes.
- Published in:
- 2011
- By:
- Publication type:
- Letter
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis.
- Published in:
- JAMA: Journal of the American Medical Association, 2011, v. 305, n. 24, p. 2556, doi. 10.1001/jama.2011.860
- By:
- Publication type:
- Article
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis.
- Published in:
- Annals of Medicine, 2022, v. 54, n. 1, p. 1287, doi. 10.1080/07853890.2022.2059559
- By:
- Publication type:
- Article
INTERASPIRE: an International Survey of Coronary Patients; Their Cardiometabolic, Renal and Biomarker Status; and the Quality of Preventive Care Delivered in All WHO Regions: In Partnership with the World Heart Federation, European Society of Cardiology, Asia Pacific Society of Cardiology, InterAmerican Society of Cardiology, and PanAfrican Society of Cardiology
- Published in:
- Current Cardiology Reports, 2021, v. 23, n. 10, p. 1, doi. 10.1007/s11886-021-01568-2
- By:
- Publication type:
- Article
Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Ethnicity-specific association of BMI levels at diagnosis of type 2 diabetes with cardiovascular disease and all-cause mortality risk.
- Published in:
- Acta Diabetologica, 2019, v. 56, n. 1, p. 87, doi. 10.1007/s00592-018-1219-7
- By:
- Publication type:
- Article
Role of Cardiovascular Imaging in Risk Assessment: Recent Advances, Gaps in Evidence, and Future Directions.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 17, p. 5563, doi. 10.3390/jcm12175563
- By:
- Publication type:
- Article
The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 23, p. 5656, doi. 10.3390/jcm10235656
- By:
- Publication type:
- Article
Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 19, p. 4472, doi. 10.3390/jcm10194472
- By:
- Publication type:
- Article
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.
- Published in:
- Cardiovascular Research, 2024, v. 120, n. 12, p. 1400, doi. 10.1093/cvr/cvae109
- By:
- Publication type:
- Article
Correction to: Role of Bempedoic Acid in Clinical Practice.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Role of Bempedoic Acid in Clinical Practice.
- Published in:
- Cardiovascular Drugs & Therapy, 2021, v. 35, n. 4, p. 853, doi. 10.1007/s10557-021-07147-5
- By:
- Publication type:
- Article
Individual and joint associations of obesity and metabolic health parameters on arterial stiffness: Evidence from the UK Biobank.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 899, doi. 10.1111/dom.16090
- By:
- Publication type:
- Article
Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION‐9, ORION‐10 and ORION‐11 Phase 3 randomized trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3223, doi. 10.1111/dom.15650
- By:
- Publication type:
- Article
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 5, p. 868, doi. 10.1111/dom.14645
- By:
- Publication type:
- Article
A multinational observational study assessing insulin use: Understanding the determinants associated with progression of therapy.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 5, p. 1101, doi. 10.1111/dom.13622
- By:
- Publication type:
- Article
The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, p. 6, doi. 10.1111/dom.13691
- By:
- Publication type:
- Article
Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 6, p. 1479, doi. 10.1111/dom.13257
- By:
- Publication type:
- Article
Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 6, p. 1337, doi. 10.1111/dom.13243
- By:
- Publication type:
- Article
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 12, p. 1781, doi. 10.1111/dom.13114
- By:
- Publication type:
- Article
Long-term mortality after acute myocardial infarction among individuals with and without diabetes: A systematic review and meta-analysis of studies in the post-reperfusion era.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 3, p. 364, doi. 10.1111/dom.12827
- By:
- Publication type:
- Article
Metabolic syndrome is associated with similar long-term prognosis in those living with and without obesity: an analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004–2015 studies.
- Published in:
- European Journal of Preventive Cardiology, 2023, v. 30, n. 12, p. 1195, doi. 10.1093/eurjpc/zwad101
- By:
- Publication type:
- Article
Is the SMART risk prediction model ready for real-world implementation? A validation study in a routine care setting of approximately 380 000 individuals.
- Published in:
- European Journal of Preventive Cardiology, 2022, v. 29, n. 4, p. 654, doi. 10.1093/eurjpc/zwab093
- By:
- Publication type:
- Article
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DAVINCI study.
- Published in:
- European Journal of Preventive Cardiology, 2021, v. 28, n. 11, p. 1279, doi. 10.1093/eurjpc/zwaa047
- By:
- Publication type:
- Article
Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab.
- Published in:
- European Journal of Preventive Cardiology, 2020, v. 27, n. 15, p. 1663, doi. 10.1177/2047487320905185
- By:
- Publication type:
- Article
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
- Published in:
- European Journal of Preventive Cardiology, 2020, v. 27, n. 6, p. 593, doi. 10.1177/2047487319864671
- By:
- Publication type:
- Article
Will genetic studies deliver the next generation of cardioprotective therapies?
- Published in:
- 2017
- By:
- Publication type:
- Editorial
Will genetic studies deliver the next generation of cardioprotective therapies?
- Published in:
- 2017
- By:
- Publication type:
- Editorial
The need for a new classification of cholesterol lowering therapies.
- Published in:
- 2017
- By:
- Publication type:
- Letter
Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives.
- Published in:
- European Heart Journal, 2023, v. 44, n. 43, p. 4499, doi. 10.1093/eurheartj/ehad632
- By:
- Publication type:
- Article
The global diagnostic network: what can we learn from half a billion lipid measurements between 2018 and 2020?
- Published in:
- European Heart Journal, 2023, v. 44, n. 25, p. 2319, doi. 10.1093/eurheartj/ehad308
- By:
- Publication type:
- Article
Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
- Published in:
- European Heart Journal, 2023, v. 44, n. 16, p. 1408, doi. 10.1093/eurheartj/ehad144
- By:
- Publication type:
- Article
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.
- Published in:
- European Heart Journal, 2023, v. 44, n. 2, p. 129, doi. 10.1093/eurheartj/ehac594
- By:
- Publication type:
- Article
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.
- Published in:
- European Heart Journal, 2022, v. 43, n. 48, p. 5047, doi. 10.1093/eurheartj/ehac615
- By:
- Publication type:
- Article
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
- Published in:
- European Heart Journal, 2022, v. 43, n. 39, p. 3925, doi. 10.1093/eurheartj/ehac361
- By:
- Publication type:
- Article
Combination lipid-lowering therapy as first-line strategy in very high-risk patients.
- Published in:
- European Heart Journal, 2022, v. 43, n. 8, p. 830, doi. 10.1093/eurheartj/ehab718
- By:
- Publication type:
- Article
Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care.
- Published in:
- European Heart Journal, 2021, v. 42, n. 3, p. 253, doi. 10.1093/eurheartj/ehaa1008
- By:
- Publication type:
- Article
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
- Published in:
- European Heart Journal, 2020, v. 41, n. 44, p. 4245, doi. 10.1093/eurheartj/ehaa649
- By:
- Publication type:
- Article
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.
- Published in:
- European Heart Journal, 2020, v. 41, n. 24, p. 2304, doi. 10.1093/eurheartj/ehz778
- By:
- Publication type:
- Article
The year in cardiology: cardiovascular prevention: The year in cardiology 2019.
- Published in:
- European Heart Journal, 2020, v. 41, n. 11, p. 1157, doi. 10.1093/eurheartj/ehz929
- By:
- Publication type:
- Article
Lp(a) and cardiovascular disease—Has the phoenix finally risen from the ashes?
- Published in:
- European Heart Journal, 2019, v. 40, n. 33, p. 2771, doi. 10.1093/eurheartj/ehz016
- By:
- Publication type:
- Article
Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2540, doi. 10.1093/eurheartj/ehx450
- By:
- Publication type:
- Article
‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2546, doi. 10.1093/eurheartj/ehx710
- By:
- Publication type:
- Article
Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2526, doi. 10.1093/eurheartj/ehy182
- By:
- Publication type:
- Article
Cardiac rehabilitation versus standard care after aortic aneurysm repair (Aneurysm CaRe): study protocol for a randomised controlled trial.
- Published in:
- Trials, 2015, v. 16, n. 1, p. 1, doi. 10.1186/s13063-015-0669-2
- By:
- Publication type:
- Article
Cardiac rehabilitation versus standard care after aortic aneurysm repair (Aneurysm CaRe): study protocol for a randomised controlled trial.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial.
- Published in:
- Cardiovascular Diabetology, 2021, v. 20, n. 1, p. 1, doi. 10.1186/s12933-021-01311-9
- By:
- Publication type:
- Article